This article is more than 5 years old. Information may no longer be current.

Ivantis secures additional $25 million in Series B financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ivantis announced it has secured an additional $25 million in its Series B financing, bringing the total Series B financing to $71 million, according to a company press release.

Investors included in the latest closure are Foresite Capital, New Enterprise Associates, Delphi Ventures, Ascension Ventures, Vertex Ventures, GBS Ventures, EDBI, and MemorialCare Innovation Fund.

The latest funds will support Ivantis’ ongoing clinical trials, including a pivotal U.S. trial for the company’s Hydrus microstent, designed to alleviate eye pressure in patients with glaucoma.

The trial is currently evaluating the device in glaucoma patients undergoing cataract surgery; however, the device is also being used internationally in both cataract surgery and standalone glaucoma surgery, according to the press release.